'We are lowering our prices' in the U.S. says Novo Nordisk CFO
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a day ago
- Yahoo
Why Novo Nordisk Flew Almost 3% Higher on Friday
Key Points The company's leading product looked more attractive following price hikes by a competitor. Eli Lilly's Zepbound will become more expensive in the U.K. and likely throughout Europe subsequently. 10 stocks we like better than Novo Nordisk › An archrival's pricing move was seen as beneficial for Novo Nordisk (NYSE: NVO) on Friday. As investors disseminated news of a dramatic increase in the cost of a product competing with the company's star drug, Wegovy, they pushed the Danish pharmaceutical company's share price up. It closed the day almost 3% higher during a session when the S&P 500 index ended up slumping by 0.3%. A rival's hikes The previous day, U.S. healthcare giant Eli Lilly announced that it was raising the prices of Zepbound -- a GLP-1 obesity drug that directly competes with Wegovy -- in the U.K. In doing so, the company indicated that it will follow suit in other European markets. The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S. drug companies, stating that they had until Sept. 29 to reduce the costs of certain medications. Failure to do so, the president wrote somewhat vaguely, would see the federal government "deploy every tool in our arsenal to protect American families." Although Novo Nordisk also received one of these letters -- there were 17 in all -- the company hasn't given any concrete indication that it intends to make adjustments similar to Eli Lilly's. Customer rebellion brewing? For the moment, then, Novo Nordisk enjoys a bit of an advantage, as there is inevitably customer backlash (and often defection to rival products) when a company hikes prices. We've yet to see how Trump's initiative will fully play out, however. So, personally, I don't think any investor should base their Novo Nordisk stance on the Eli Lilly development. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Flew Almost 3% Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years
Key Points The stocks listed below have excellent fundamentals. But they've all been experiencing headwinds recently. All of them trade at around 13 times their trailing earnings. 10 stocks we like better than Lululemon Athletica Inc. › If you want a good, deep value stock to buy, you often need to take on some risk, or at least accept some short-term uncertainty. But that patience can pay off in the long run. There are many examples of quality stocks out there that people have simply given up on, but that are by no means doomed. Three stocks that fall into that category today include Lululemon Athletica (NASDAQ: LULU), Novo Nordisk (NYSE: NVO), and United Parcel Service (NYSE: UPS). They aren't simply trading near their 52-week lows; they are also at levels they haven't been at in multiple years. Lululemon Athletica Shares of apparel maker Lululemon have been crashing this year. The company has lost around half of its value since January as tariffs are weighing on its growth potential. The company relies heavily on Asia for its manufacturing, and China is also a key market for Lululemon. As a result of the U.S. imposing tariffs on many countries, and particularly targeting China, shares of Lululemon have been in a free fall. When it last reported earnings in June, the company projected single-digit net revenue growth of at least 5% for the full year. But with an evolving and changing situation related to tariffs, that guidance comes with an asterisk. Not only could its earnings decline as a result of rising costs, but there could also be less demand for Lululemon's premium-priced apparel if macroeconomic conditions around the world deteriorate due to trade wars. Lululemon is, however, still a popular brand with young people, and it holds a lot of value. The stock is now trading at levels it hasn't been at since 2020. It's at a price-to-earnings (P/E) multiple of 13, which would normally be a steal of a deal if not for the question marks looming around its business. If you're willing to take on some risk and hang on amid the current uncertainty, Lululemon could be a good buy today. But the safer option may be to wait until it reports earnings in the coming weeks to get an update of its situation, and then reevaluate the stock. Novo Nordisk Shares of Ozempic maker Novo Nordisk are also down big this year, falling by more than 40% thus far in 2025. The company has replaced its CEO and also cut its guidance this year as it's facing rising competition in the GLP-1 drug market. Novo still projects sales growth between 8% and 14% this year, but that's down from a previous estimate of 13% to 21%. While it's disappointing to see the pharma company cut its guidance, there's still tremendous growth potential for its GLP-1 drugs in the future, particularly as they accumulate more indications. Regulators in the U.S. have recently expanded Ozempic's use to also treat chronic kidney disease. And a recent study suggests it may also help reduce the risk of Alzheimer's. Novo Nordisk is also taking legal action to take knockoff versions of its GLP-1 products off the market. Doing so could help drive people to buy its FDA-approved treatments instead, and thus bolster its growth rate in the process. With the stock trading at just 13 times its trailing earnings -- levels it hasn't been at since 2022 -- Novo Nordisk is a terrific buy right now. United Parcel Service United Parcel Service, or UPS as it's usually called, is another stock that's been struggling mightily this year, down more than 30%. With global uncertainty due to tariffs, the current macroeconomic environment is far from an ideal one for the logistics giant to be operating in. Investors, anticipating a slowdown in global shipments, have been quick to dump UPS' stock. The company's sales were flat last quarter, and the problem is that things may get worse in upcoming periods, as companies grapple with tariffs and how best to navigate around them. There is the potential for trade to slow significantly, which would be bad news for UPS's business. But the good news is that the company is still profitable and it has been slashing jobs in an effort to cut costs and become leaner and more efficient. In the long run, this is still a great business to invest in as it benefits from economic growth all over the world. Even if you're worried about the short term, UPS can be a good investment to hang on to for the long haul. The stock trades at a P/E ratio of just 13, and it hasn't been this cheap since 2013. Should you buy stock in Lululemon Athletica Inc. right now? Before you buy stock in Lululemon Athletica Inc., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lululemon Athletica Inc. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 David Jagielski has positions in Novo Nordisk. The Motley Fool has positions in and recommends Lululemon Athletica Inc. and United Parcel Service. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years was originally published by The Motley Fool Sign in to access your portfolio
